HPV vaccine shows promise for chinese women and girls in large trial
NCT ID NCT03903562
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 study tested a 9-valent HPV vaccine in nearly 2,000 healthy Chinese females aged 9 to 45. The goal was to see if the vaccine triggers a strong immune response and is safe. Participants received three doses, and researchers measured antibody levels over five years, especially in younger participants. The results could support broader use of this vaccine in China to help prevent HPV infections and related cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
9-valent human papillomavirus (HPV) vaccine
What this could lead to
If successful, this could confirm that the 9-valent HPV vaccine is safe and produces a strong immune response in Chinese females aged 9-45, supporting its use to prevent HPV infections and related cancers.
What could go wrong
This is a completed Phase 3 trial, so results are already in. However, the study only measured immune response, not actual prevention of infection or cancer. Long-term effectiveness and real-world impact still need further study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPILLOMAVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaihua country Center for Disease Control and Prevention ( Site 0002)
Quzhou, Zhejiang, 324300, China
-
Shaoxing keqiao center for disease prevention and control ( Site 0001)
Shaoxing, Zhejiang, 312030, China